HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hepatic toxicity of low doses of mithramycin in hypercalcemia.

Abstract
The medical records of patients receiving mithramycin for the treatment of hypercalcemia at The Johns Hopkins Oncology Center were reviewed. Of 67 evaluable patients, 11 (16%) developed hepatic toxicity when graded using standard criteria. The pattern of laboratory abnormalities noted suggested mild hepatocellular damage that was reversible within 2 weeks. Review of these patients did not identify factors which predispose to hepatic toxicity, although failure to do so may reflect the limited number of toxic patients evaluated. Mild, reversible hepatic dysfunction appears to be a more common sequela of mithramycin administration than has previously been recognized.
AuthorsL Green, R C Donehower
JournalCancer treatment reports (Cancer Treat Rep) Vol. 68 Issue 11 Pg. 1379-81 (Nov 1984) ISSN: 0361-5960 [Print] United States
PMID6238672 (Publication Type: Journal Article)
Chemical References
  • Plicamycin
Topics
  • Chemical and Drug Induced Liver Injury
  • Humans
  • Hypercalcemia (drug therapy)
  • Liver (drug effects)
  • Liver Diseases (enzymology)
  • Plicamycin (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: